Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3349MR)

This product GTTS-WQ3349MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3349MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5629MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ10142MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ439MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ6195MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ7959MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15681MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ13860MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ2602MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 531
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW